Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation

NCT06050980 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC

Interventions

DRUG: HSK40118

Sponsor

Haisco Pharmaceutical Group Co., Ltd.